BioCentury | Jun 26, 2020
Finance

Akouos’ first-day pop outshines peers among NASDAQ IPO trio

...first-day rise of 29% was the biggest, while Fusion gave back its early gains and PolyPid...
...Life Sciences. Underwriters are Morgan Stanley, Jefferies, Cowen and Wedbush PacGrow (see “Radio Fusion” ). PolyPid Ltd....
...IGF1R (CD221) - Insulin-like growth factor-1 receptor OTOF - Otoferlin Paul Bonanos, Associate Editor Akouos Inc. Fusion Pharmaceuticals Inc. PolyPid Ltd....
BioCentury | Jun 26, 2020
Finance

Poseida brings in $110M ahead of IPO as more biotechs line up for NASDAQ debuts

...it filed last week to sell 8.4 million shares. Also expected to price Thursday is PolyPid Ltd....
BioCentury | Jun 24, 2020
Finance

June 23 Quick Takes: Illumina selects first biotechs for U.K. accelerator; plus updates from the NASDAQ IPO queue, and venture rounds for Surrozen, Tara

...at the midpoint, the hearing loss gene therapy company would be valued at $424.7 million. PolyPid Ltd....
...Targets WNT - Wingless-type MMTV integration site family Elizabeth S. Eaton, Staff Writer Illumina Inc. Fusion Pharmaceuticals Inc. Akouos Inc. PolyPid Ltd. Amryt...
BioCentury | Jun 9, 2020
Finance

Next up on NASDAQ: trio of preclinical companies ready for debuts, plus new filings

...Fusion Pharmaceuticals Inc.; and diagnostics companies Genetron Holdings Ltd. and ArcherDX Inc. Drug delivery company PolyPid Ltd....
...LLC Burning Rock Biotech Royalty Pharma Legend Biotechnology Corp. Arya Sciences Acquisition Corp. Lantern Pharma Inc. Akouos Inc. Fusion Pharmaceuticals Inc. Genetron Holdings Ltd. PolyPid Ltd. IPO...
BioCentury | Sep 4, 2019
Financial News

Sept. 4 Financial Quick Takes: BrightGene looks to STAR; plus IPO updates from Immunotech, 10x Genomics, SpringWorks, IGM, Satsuma and more

...shares. Underwriters are Jefferies, Cowen, Guggenheim, Baird and Bloom Burton. PolyPid closes $50M series E-1 PolyPid Ltd....
...a broad-spectrum antibiotic to prevent surgical site infections, in two Phase III trials. BC Staff D-PLEX EAL BrightGene Immunotech Biopharm Ltd. PolyPid Ltd....
BioCentury | Feb 29, 2016
Financial News

PolyPid completes venture financing

PolyPid Ltd. , Petah Tikva, Israel Business: Drug delivery Date completed: 2016-02-24 Type: Venture financing Raised: $22 million Investors: Shavit Capital; Aurum Ventures; company director; existing investors WIR Staff...
BioCentury | Feb 25, 2016
Financial News

PolyPid's D round brings in $22M

...Chaim Hurvitz, who will now head PolyPid's board, and undisclosed other existing shareholders also participated. PolyPid...
...secured antibiotic drug reservoir intended to provide prolonged local protection from infection. In March 2015, PolyPid...
BioCentury | Mar 30, 2015
Financial News

PolyPid withdraws IPO

...Drug delivery Date announced: 2015-03-26 Type: IPO Underwriters: Aegis Capital; MLV; Chardan Capital Markets Note: PolyPid...
BioCentury | Mar 28, 2015
Financial News

PolyPid withdraws IPO

...anticipates undisclosed milestones in the next few months that could boost its valuation. In January, PolyPid...
...Markets. At $11, it would have raised $20 million and been valued at $106.3 million. PolyPid's...
BioCentury | Jan 5, 2015
Finance

2015 Financial Markets Preview: Show me in 2015

...BioPharma Inc. (C) 11/24/14 TBD Preclin Inotek Pharmaceuticals Corp. 11/4/14 Up to $86.3M Ph II PolyPid Ltd....
Items per page:
1 - 10 of 21
BioCentury | Jun 26, 2020
Finance

Akouos’ first-day pop outshines peers among NASDAQ IPO trio

...first-day rise of 29% was the biggest, while Fusion gave back its early gains and PolyPid...
...Life Sciences. Underwriters are Morgan Stanley, Jefferies, Cowen and Wedbush PacGrow (see “Radio Fusion” ). PolyPid Ltd....
...IGF1R (CD221) - Insulin-like growth factor-1 receptor OTOF - Otoferlin Paul Bonanos, Associate Editor Akouos Inc. Fusion Pharmaceuticals Inc. PolyPid Ltd....
BioCentury | Jun 26, 2020
Finance

Poseida brings in $110M ahead of IPO as more biotechs line up for NASDAQ debuts

...it filed last week to sell 8.4 million shares. Also expected to price Thursday is PolyPid Ltd....
BioCentury | Jun 24, 2020
Finance

June 23 Quick Takes: Illumina selects first biotechs for U.K. accelerator; plus updates from the NASDAQ IPO queue, and venture rounds for Surrozen, Tara

...at the midpoint, the hearing loss gene therapy company would be valued at $424.7 million. PolyPid Ltd....
...Targets WNT - Wingless-type MMTV integration site family Elizabeth S. Eaton, Staff Writer Illumina Inc. Fusion Pharmaceuticals Inc. Akouos Inc. PolyPid Ltd. Amryt...
BioCentury | Jun 9, 2020
Finance

Next up on NASDAQ: trio of preclinical companies ready for debuts, plus new filings

...Fusion Pharmaceuticals Inc.; and diagnostics companies Genetron Holdings Ltd. and ArcherDX Inc. Drug delivery company PolyPid Ltd....
...LLC Burning Rock Biotech Royalty Pharma Legend Biotechnology Corp. Arya Sciences Acquisition Corp. Lantern Pharma Inc. Akouos Inc. Fusion Pharmaceuticals Inc. Genetron Holdings Ltd. PolyPid Ltd. IPO...
BioCentury | Sep 4, 2019
Financial News

Sept. 4 Financial Quick Takes: BrightGene looks to STAR; plus IPO updates from Immunotech, 10x Genomics, SpringWorks, IGM, Satsuma and more

...shares. Underwriters are Jefferies, Cowen, Guggenheim, Baird and Bloom Burton. PolyPid closes $50M series E-1 PolyPid Ltd....
...a broad-spectrum antibiotic to prevent surgical site infections, in two Phase III trials. BC Staff D-PLEX EAL BrightGene Immunotech Biopharm Ltd. PolyPid Ltd....
BioCentury | Feb 29, 2016
Financial News

PolyPid completes venture financing

PolyPid Ltd. , Petah Tikva, Israel Business: Drug delivery Date completed: 2016-02-24 Type: Venture financing Raised: $22 million Investors: Shavit Capital; Aurum Ventures; company director; existing investors WIR Staff...
BioCentury | Feb 25, 2016
Financial News

PolyPid's D round brings in $22M

...Chaim Hurvitz, who will now head PolyPid's board, and undisclosed other existing shareholders also participated. PolyPid...
...secured antibiotic drug reservoir intended to provide prolonged local protection from infection. In March 2015, PolyPid...
BioCentury | Mar 30, 2015
Financial News

PolyPid withdraws IPO

...Drug delivery Date announced: 2015-03-26 Type: IPO Underwriters: Aegis Capital; MLV; Chardan Capital Markets Note: PolyPid...
BioCentury | Mar 28, 2015
Financial News

PolyPid withdraws IPO

...anticipates undisclosed milestones in the next few months that could boost its valuation. In January, PolyPid...
...Markets. At $11, it would have raised $20 million and been valued at $106.3 million. PolyPid's...
BioCentury | Jan 5, 2015
Finance

2015 Financial Markets Preview: Show me in 2015

...BioPharma Inc. (C) 11/24/14 TBD Preclin Inotek Pharmaceuticals Corp. 11/4/14 Up to $86.3M Ph II PolyPid Ltd....
Items per page:
1 - 10 of 21